Annals of Hematology

, Volume 88, Issue 7, pp 607–611

Meeting report: Vienna 2008 Workshop of the German–Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes

Authors

    • Department of Internal Medicine I, Division of Hematology & HemostaseologyMedical University of Vienna
  • Wolf-Karsten Hofmann
    • Department of Hematology, Oncology and Transfusion MedicineCharité University Hospital
  • Guntram Büsche
    • Institute of PathologyMedizinische Hochschule Hannover
  • Karl Sotlar
    • Institute of PathologyLudwig-Maximilians-Universität München
  • Hans-Peter Horny
    • Klinikum Ansbach, Institute of Pathology
  • Detlef Haase
    • Department of Hematology and OncologyGeorg-August-University
  • Torsten Haferlach
    • MLL Munich Leukemia Laboratory
  • Wolfgang Kern
    • MLL Munich Leukemia Laboratory
  • Peter Bettelheim
    • Institute for Laboratory MedicineOtto Wagner Hospital Vienna
  • Christian Baumgartner
    • Department of Internal Medicine I, Division of Hematology & HemostaseologyMedical University of Vienna
  • Wolfgang R. Sperr
    • Department of Internal Medicine I, Division of Hematology & HemostaseologyMedical University of Vienna
  • Thomas Nösslinger
    • Ludwig-Boltzmann Institute for Leukemia Research and HematologyHanusch Hospital
  • Friedrich Wimazal
    • Department of Internal Medicine I, Division of Hematology & HemostaseologyMedical University of Vienna
  • Aristoteles A. Giagounidis
    • Medizinische Klinik IISt. Johannes Hospital Duisburg
  • Michael Lübbert
    • Division of Hematology/Oncology, Department of MedicineUniversity of Freiburg
  • Otto Krieger
    • First Department of Internal MedicineElisabethinen Hospital
  • Hans-Jochem Kolb
    • Department of Medicine IIIUniversity of Munich, GSF-National Research Centre for Environment and Health
  • Reinhard Stauder
    • Division of Hematology and OncologyInnsbruck Medical University
  • Michael Pfeilstöcker
    • Ludwig-Boltzmann Institute for Leukemia Research and HematologyHanusch Hospital
  • Norbert Gattermann
    • Department of Hematology Oncology and Clinical ImmunologyHeinrich-Heine-University
  • Christa Fonatsch
    • Department of Medical GeneticsMedical University of Vienna
  • Carlo Aul
    • Medizinische Klinik IISt. Johannes Hospital Duisburg
  • Ulrich Germing
    • Department of Hematology Oncology and Clinical ImmunologyHeinrich-Heine-University
Original Article

DOI: 10.1007/s00277-008-0673-7

Cite this article as:
Valent, P., Hofmann, W., Büsche, G. et al. Ann Hematol (2009) 88: 607. doi:10.1007/s00277-008-0673-7

Abstract

Criteria, scoring systems, and treatment algorithms for myelodysplastic syndromes (MDS) have been updated repeatedly in recent years. This apparently results from increased awareness and early recognition of the disease, an increasing number of new diagnostic and prognostic markers and tools, and new therapeutic options that may change the course and thus prognosis in MDS. To address these challenges and to create useful new diagnostic and prognostic parameters and scores, the German–Austrian Working Group for Studying Prognostic Factors in MDS was established in 2003 and later was extended to centers in Switzerland (D-A-CH group). In addition, the group cooperates with the European LeukemiaNet, the MDS Foundation, and other national and international working groups in order to improve diagnosis and prognostication. The current article represents a meeting report from the latest workshop organized by the group in Vienna in October 2008.

Keywords

Myelodysplastic syndromesCriteriaPrognosticationStandardizationMDS registry

Copyright information

© Springer-Verlag 2009